Cargando…
Measuring Treatment Response in Progressive Multiple Sclerosis—Considerations for Adapting to an Era of Multiple Treatment Options
Disability in multiple sclerosis accrues predominantly in the progressive forms of the disease. While disease-modifying treatment of relapsing MS has drastically evolved over the last quarter-century, the development of efficient drugs for preventing or at least delaying disability in progressive MS...
Autores principales: | Krajnc, Nik, Berger, Thomas, Bsteh, Gabriel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470215/ https://www.ncbi.nlm.nih.gov/pubmed/34572555 http://dx.doi.org/10.3390/biom11091342 |
Ejemplares similares
-
Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review
por: Krajnc, Nik, et al.
Publicado: (2021) -
Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management
por: Krajnc, Nik, et al.
Publicado: (2022) -
Has the pandemic changed treatment strategy in multiple sclerosis?
por: Bsteh, Gabriel, et al.
Publicado: (2022) -
Remote visits for people with multiple sclerosis during the COVID-19
pandemic in Austria: The TELE MS randomized controlled trial
por: Altmann, Patrick, et al.
Publicado: (2022) -
Association of Cerebrospinal Fluid Parameters and Neurofilament Light Chain With Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
por: Krajnc, Nik, et al.
Publicado: (2022)